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Hospital Hietzing, Vienna, Austria.BACKGROUND Transcatheter aortic valve implantation (TAVI) has
become the standard therapy for high-risk and non-operable
patients with severe aortic stenosis. However, the procedure
involves several adverse effects, such as rhythm and conduction
disturbances. Patients with postprocedural left bundle branch block
may have an increased mortality risk, whereas patients with
preprocedural right bundle branch block display a higher rate of
postinterventional bradyarrhythmias.
OBJECTIVE The purpose of this study was to investigate the
occurrence of high-degree atrioventricular block (AVB) in patients
with preexisting bundle branch block (BBB) or BBB occurring
during TAVI.
METHODS In this prospective single-center study, 50 consecutive
patients undergoing TAVI with the Medtronic CoreValve Revalving
System were included. Of these patients, 17 with preexisting BBB or
BBB occurring during TAVI received a primary prophylactic perma-
nent DDD pacemaker, programmed to the SafeR-mode and featuring
dual-channel event counters as well as stored intracardiac electro-
grams. Pacemaker readouts and intracardiac electrograms were
analyzed for the occurrence of high-degree AVB.
RESULTS Ten of 17 patients (58.8%) with preexisting BBB or BBB
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1547-5271/ B 2014 Heart Rhythm Society. Open access under CC BY-NC-ND licensewere immediately terminated due to switch into DDD backup
pacing. In 5 of the cases (29.4%), the ﬁrst documented episode
of high-degree AVB occurred after hospital discharge. Mean follow-
up period was 578.1  294.9 days.
CONCLUSION Development of high-degree AVB is a common
complication in patients with preexisting BBB or BBB occurring
during TAVI. Accordingly, intensiﬁed monitoring might be reason-
able, especially in patients treated with the self-expandable
Medtronic CoreValve Revalving System.
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Transcatheter aortic valve implantation (TAVI) is a proce-
dure being increasingly offered to high-risk nonoperable
patients with severe aortic stenosis (AS).1 TAVI has enabled
access to aortic valve replacement for patients who until now
have not been accepted for surgery because of the high
perioperative risk. Despite the beneﬁts, this procedure
involves several undesirable side effects, such as stroke,
vascular access site complications, and acute kidney
injury.2,3http://dx.doi.org/10.1016/j.hrthm.2014.07.014.
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Medtronic CoreValve Revalving System, some of the most
frequent complications are rhythm and conduction distur-
bances.4,5 As a consequence, permanent pacemaker (PM)
implantation is performed, with reported rates between 18%
and 49%.6–8 According to the current ACC/AHA/HRS
guidelines, permanent PM implantation is only recom-
mended in cases of symptomatic and/or high-degree
AVB.9 Except for these established indications, there is no
generally accepted strategy for PM implantation in patients
with preexisting or periprocedurally acquired conduction
disturbances. However, recent publications show that new-
onset left bundle branch block (LBBB) especially but also
QRS prolongation in general are important and independent
risk factors for all-cause mortality after TAVI.10,11 More-
over, patients with preexisting right bundle branch block
have an increased risk for the occurrence of postprocedural
bradyarrhythmia and episodes of high-degree AVB neces-
sitating permanent PM implantation.12,13
Cardiac asynchrony, which has been thoroughly inves-
tigated in animal models and in patients with heart failure,
could be responsible for the negative inﬂuence of QRS
prolongation on survival.10,14–16 In addition, the occurrence
of high-degree AVB might have a negative impact on the
outcome of these patients. Conduction abnormalities occur-
ring in the context of TAVI procedures are conceivably
caused by mechanical trauma of the cardiac conduction
system. Recent data show a distinct correlation between
positioning of the valve prosthesis and the prevalence of
LBBB.17,18 However, a “progression” from bundle branch
block (BBB) to high-degree AVB has not yet been exam-
ined. Therefore, we investigated the incidence of high-
degree AVB (type 2 second-degree AVB and complete
AVB) in patients with preexisting BBB or BBB occurring
during TAVI.Methods
Patient population
Between August 2010 and December 2012, 50 consecutive
patients undergoing TAVI were prospectively investigated at
our department. Inclusion criteria comprised an aortic valve
area of r1cm2 or r0.6cm2/m2 or/and a transvalvular
gradientZ40 mm Hg. Each patient was evaluated for TAVI
by a local heart team consisting of interventional cardiolo-
gists and cardiac surgeons. Surgical risk stratiﬁcation was
performed using the logistic European system for cardiac
operative risk evaluation score (EuroSCORE). In case of
high risk or inoperability, TAVI was the offered treatment.
Baseline and procedural parameters were collected for all
patients. Furthermore, intracardiac electrograms (EGMs)
were performed in patients with preexisting BBB or BBB
occurring during TAVI and prophylactic permanent PM
implantation. Patients with a preexisting permanent PM or
permanent atrial ﬁbrillation were excluded from this analysis
because it was not possible to assess intracardiac EGM
recordings of AVB episodes in this setting. The study wasconducted in accordance with the Declaration of Helsinki
and the local ethics review committee.
Procedure
Implantation of the bioprosthesis was performed in a routine
manner as described elsewhere.19 In brief, all patients
received the self-expanding third-generation CoreValve
Revalving System (Medtronic, Minneapolis, MN), which
consists of a trileaﬂet porcine pericardial valve attached to a
nitinol stent frame. The bioprosthesis was used in sizes of 26,
29, and 31 mm and was implanted exclusively through the
transfemoral route under general anesthesia after surgical
preparation of the femoral artery. Outcome parameters were
assessed in accordance with the Valve Academic Research
Consortium (VARC) criteria.
Superﬁcial ECGs and intracardiac EGMs
A baseline 12-lead ECG was collected before TAVI or
before prophylactic PM implantation. Rhythm, heart rate,
and PR, QRS, and corrected PQ intervals were measured.
Periprocedural rhythm and conduction disturbances were
monitored by permanent 3-lead ECG surveillance followed
by continuous rhythm monitoring for 48 hours after the
intervention. All patients received a temporary right ven-
tricular pacemaker that was removed if conduction disorders
were absent 48 hours after the implantation. If episodes of
high-degree AVB were detected, permanent PM implanta-
tion was performed. According to our standard operating
procedures, a permanent PM (Sorin Reply/Symphony with
AVB documentation in AIDA memories, Milano, Italy) was
also implanted in case of preexisting BBB or BBB occurring
during TAVI. All procedures were conducted under local
anesthesia and dual antiplatelet therapy if performed after
TAVI. The devices were programmed in the SafeR-mode,
which allows intrinsic conduction and switch to DDD mode
in the event of atrioventricular (AV) conduction disturbances
(ﬁrst- and second-degree AVB, complete AVB, and pauses
42 seconds). The unique feature of stored intracardiac
EGMs of AV conduction disturbances was the main reason
to implant such devices. AIDA software facilitated the
documentation and analysis of stored intracardiac EGMs
and allowed continuous monitoring of AV conduction.20 In
case of ventricular pacing rates below 1%, the PM software
displays “o1%.” For calculation purposes, these values
were counted as 0.9%. Two senior cardiologists (MN, PS)
reviewed all ECGs and intracardiac EGMs, in order to
discriminate between true high-degree AV conduction
abnormalities and incidents erroneously recorded by the
PM software. ECG changes were reported in accordance
with the AHA/ACCF/HRS recommendations for the stand-
ardization and interpretation of the ECG.21
Follow-up
After an initial PM checkup within 3 months of implantation,
routine follow-up visits were scheduled at least annually at
our outpatient ward. At every follow-up visit, outcome and
Figure 1 Study population. Categorization made using baseline and
postprocedural ECG characteristics. BBB ¼ bundle branch block; PM ¼
pacemaker; TAVI ¼ transcatheter aortic valve implantation.
Heart Rhythm, Vol 11, No 12, December 20142178end-point data were assessed. All patients were referred for
pacemaker checkup and transthoracic echocardiography.
Clinical, functional, and biochemical parameters were col-
lected. Rhythm and conduction disturbances were evaluated
with 12-lead ECG records and readouts of AVB documen-
tation in AIDA memories.Statistical analysis
Categorical variables are reported as frequency count and
percentage. Differences between groups were investigated using
the χ2 or Fisher exact test, as required. Continuous variables are
reported as mean with SD or as median with interquartile range.
Normal distribution was conﬁrmed by the Shapiro–Wilk test.
Groups were compared by the Wilcoxon–Mann–Whitney test
or t test, whichever was appropriate. Signiﬁcance was assumedFigure 2 Details of preexisting and postprocedural new-onset conduction abnorm
degree atrioventricular block; BBB¼ bundle branch block; LAFB¼ left anterior fa
¼ right bundle branch block.in case of 2-sided P r.05. Statistical analysis was conducted
using SPSS 20 (IBM Corp, Armonk, NY).
Results
Study population
Of the 50 patients who were treated with TAVI, 31 patients
were not eligible for the following reasons: 20 either presented
with permanent atrial ﬁbrillation or already had a permanent
PM implanted; 2 patients died periprocedurally; 4 patients
showed unimpaired conduction; 1 patient showed left anterior
fascicular block (LAFB) before and after the intervention; and
therapeutic permanent PM implantation was necessary in 3
patients with normal conduction and in 1 patient with LAFB at
baseline but complete AVB after the procedure.
In 19 patients, preexisting BBB or BBB occurring during
TAVI was present. One of these patients died before a
permanent PM could be implanted. A second patient did not
receive a permanent PM at the discretion of the intervention-
alist. The remaining 17 patients with a documented preexist-
ing BBB or BBB occurring during TAVI had a prophylactic
permanent PM implanted and were eligible for assessment of
rhythm and conduction disturbances. The study population is
depicted in Figure 1. Details on preexisting and postproce-
dural new-onset conduction disturbances are shown in
Figure 2. Table 1 gives the baseline characteristics of the
whole patient collective and of the patients with prophylactic
permanent PM implantation, respectively.
TAVI procedure and PM implantation
Valve dimensions of 26, 29, and 31 mm were used in 32, 17,
and 1 case, respectively. Acute procedural success rate was
94.0% (n ¼ 47). Immediate procedural mortality (death
within 72 hours of TAVI) was 4.0% (n ¼ 2): 1 patient died
due to rupture of the aortic annulus after balloonalities. AF¼ atrial ﬁbrillation; AVB¼ atrioventricular block; AVB I¼ ﬁrst-
scicular block; LBBB¼ left bundle branch block; PM¼ pacemaker; RBBB
Table 1 Baseline characteristics of the whole study population
and patients with prophylactic permanent PM implantation
All patients
(n¼50)
Prophylactic PM
(n¼17)
Clinical paramenters
Age (years) 84.0 (78.8–87.0) 83.0 (80.0–85.5)
Gender (male) 16 (32.0%) 4 (23.5%)
Aortic valve area (cm2) 0.7 (0.6–0.9) 0.7 (0.6–0.9)
NYHA level
1 0 (0.0%) 0 (0.0%)
2 7 (14.0%) 3 (17.6%)
3 39 (78.0%) 14 (82.4%)
4 4 (8.0%) 0 (0.0%)
Logistic EuroSCORE 25.6 (13.2) 25.8 (14.5)
Atrial ﬁbrillation 16 (32.0%)
Preexisting pacemaker 11 (22.0%)
Interventional parameters
Acute procedural success 47 (94.0%) 17 (100%)
30-day survival 46 (92.0%) 17 (100%)
Days in ICU 2.0 (2.0–5.0) 3.0 (2.0–6-0)
Days on ward 10.0 (7.0–14.8) 8.0 (6.5–13.5)
Days in hospital 13.0 (10.O–19.0) 13.0 (9.5–15.0)
Time (hh:mm) 02:57 (0:53) 02:41 (0:38)
Prosthesis size
26 mm 32 (64.0%) 13 (76.5%)
29 urn 17 (34.0%) 3 (17.6%)
31 mm 1 (2.0%) 1 (5.9%)
ICU ¼ intensive care unit; NYHA ¼ New York Heart Association; PM ¼
pacemaker.
Figure 3 Patient ﬂow through the study. Background colors indicate the
time of events and the setting of patients. AVB ¼ atrioventricular block;
BBB¼ bundle branch block, PM¼ pacemaker; TAVI¼ transcatheter aortic
valve implantation.
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ration with pericardial tamponade. The implantation of 2
valves was necessary once, after 1 bioprosthesis had
dislocated into the aortic arch. After an initial improvement
of the medical condition, uncontrollable systemic inﬂamma-
tory response syndrome resulted in death after the third
postprocedural day. One-month survival was 92.0% (n ¼
46).
In 10 patients with preexisting BBB, a permanent PM was
implanted 11.4  11.6 days before TAVI. In another 9
patients, BBB occurred during TAVI. Permanent PM
implantation was performed in 7 of these patients 2.3 
1.2 days after the intervention. PM lead revision was
necessary once because of dislocation of the atrial lead.
Moreover, 4 patients experienced postoperative hematoma,
which were classiﬁed as type 1 bleedings according to the
Bleeding Academic Research Consortium (BARC) classi-
ﬁcation.22 Inﬂammatory markers were temporarily elevated
in 1 patient. No further complications were documented. One
of the patients, who died within 30 days after TAVI, had
developed new-onset LBBB immediately after the proce-
dure. Permanent PM implantation was scheduled but post-
poned because of rising C-reactive protein levels. Fifteen
days after the intervention, the patient syncopated and
eventually died of intracranial hemorrhage.
AV conduction abnormalities
Altogether, 10 of 17 patients (58.8%) with preexisting BBB
or BBB occurring during TAVI and subsequent prophylacticpermanent PM implantation developed true (electronically
stored) episodes of high-degree AVB. In 5 of these patients
(29.4%), the ﬁrst documented episode occurred after hospital
discharge (Figure 3). None of these 5 patients was pacemaker
dependent at the subsequent routine clinical visit or hospital
admission (Table 2). The ventricular pacing rate of patient
subgroups during follow-up is depicted in Figure 4.
One patient who had a documented episode of high-
degree AVB 47 days after hospital discharge showed entire
resolution of the LBBB, occurring during TAVI, 5 days after
the intervention. Other than this speciﬁc case, all other
intraventricular conduction abnormalities (preexisting BBB
or BBB occurring during TAVI) persisted until the end of
follow-up.Software-based event adjudication
Altogether, intracardiac EGMs of 124 events were recorded
and classiﬁed as second-degree AVB, complete AVB, or
pause by the PM software. Only 44.4% of these stored
episodes proved to be true high-degree AVB. According to
automated event adjudication, 88.2% (n ¼ 15) of patients
with prophylactic PM implantation suffered from episodes of
high-degree AVB. After diligent validation of every docu-
mented episode, this diagnosis was only correct in 58.8%
(n ¼ 10) of the patients. Common underlying abnormalities
were paroxysmal atrial tachycardia with physiologic type 1
second-degree AVB, ventricular undersensing, or ventricular
sensing during atrial blanking, respectively.
Table 2 Rhythm and cardiac conduction and occurrence of high-degree AV conduction disturbances
12-Lead ECG Prior to TAVI 12-Lead ECG After TAVI Stored EGM during follow-up
Cons. Nr. Pat. Nr.
Permanent
PM Rhythm Conduction Rhythm Conduction
High-degree
AVB Onset
Interval
(days)
1 1 After TAVI SR Normal SR LBBB no
2 3 After TAVI SR Normal SR LBBB yes After discharge 427
3 5 Prior to TAVI SR RBBBþLAFBþAVB 1 SR high-degree AVB yes Before discharge
4 7 Prior to TAVI SR RBBBþLAFB SR high-degree AVB yes Before discharge
5 8 After TAVI SR Normal SR LBBB no
6 10 Prior to TAVI SR LBBB SR LBBB yes Before TAVI
7 12 After TAVI SR Normal SR L8BB no
8 15 After TAVI SR Normal SR LBBB no
9 18 Prior to TAVI SR LBBB SR LBBB yes Before TAVI
10 24 Prior to TAVI SR LBBBþAVB 1 SR LBBB yes After discharge 730
11 26 Prior to TAVI SR RBBBþLAFB SR RBBBþLAFB no
12 29 After TAVI SR Normal SR RBBB yes After discharge 235
13 31 Prior to TAVI SR LBBB SR LBBB no
14 42 Prior to TAVI SR RBBB SR High-degree AVB yes Before discbarge
15 44 After TAVI SR LBBBþAVB 1 SR LBBBþAVB 1 no
16 45 Prior to TAVI SR RBBBþLAFB SR RBBBþLAFBþAVB 1 yes After discharge 64
17 47 After TAVI SR Normal SR LBBB yes After discharge 47
AVB 1 ¼ ﬁrst-degree atrioventricular block; Cons. Nr. ¼ consecutive number; EGM ¼ electrogram; Interval ¼ days between hospital discharge and ﬁrst
document episode of high-degree atrioventricular block; LAFB ¼ left anterior fascicular block; LBBB ¼ left bundle branch block; Pat. Nr. ¼ patient number;
PM ¼ pacemaker; RBBB¼ right bundle branch block; SR ¼ sinus rhythm TAVI ¼ transcatheter aortic valve implanation.
Figure 4 Ventricular pacing rate (VPR) of patient subgroups depicted on
a logarithmic timeline. A: VPR of patients with high-degree atrioventricular
block (AVB) after discharge. B: VPR of patients with high-degree AVB
before transcatheter aortic valve implantation. C: VPR of patients with
periprocedural/postprocedural high-degree AVB. Pat. ¼ patient.
Heart Rhythm, Vol 11, No 12, December 20142180Discussion
The main ﬁnding of the present study is that 58.8% of
patients with preexisting BBB or BBB occurring during
TAVI with the Medtronic CoreValve Revalving System
developed episodes of high-degree AVB. Most importantly,
half of these high-degree AVB episodes initially occurred
after hospital discharge. To the best of our knowledge, this is
the ﬁrst study using continuous intracardiac EGM-based
event recording to investigate the frequency of high-degree
AVB in patients with preexisting BBB or BBB occurring
during TAVI.
Conduction disturbances after TAVI
The occurrence of BBB and AVB after TAVI has been
demonstrated in various trials and registries.2,3,5 Continuous
radial force, as well as transient tissue inﬂammation, edema,
and ischemia, have been suggested as possible reasons for
these partly transient conduction abnormalities.6,23 Urena
et al18 reported a signiﬁcantly increased rate of permanent
PM implantations due to high-degree AVB in patients with
postprocedural new-onset LBBB compared to those without
conduction abnormalities. Contradictory data concerning the
impact on prognosis of BBB occurring during TAVI have
been reported.10,17,18 Some evidence indicates that preoper-
ative or postoperative BBB in patients with surgical aortic
valve replacement is associated with an increased adverse
event rate.24 Accordingly, because of the potential severe
sequelae associated with impaired AV conduction, prophy-
lactic permanent PM implantation has been suggested
for surgically treated patients.24 Houthuizen et al10 reported
similar ﬁndings for patients with LBBB induced by TAVI.
Besides a 2-fold increase of cardiovascular mortality, the
absolute and relative mortality risk were elevated. Moreover,
2181Egger et al High-Degree AVB During Transcatheter Aortic Valve ImplantationLBBB complicating TAVI turned out to be the strongest
independent predictor of all-cause mortality. Explanations
include interventricular and intraventricular asynchrony due
to altered ventricular activation or the onset of rhythm and
conduction abnormalities, as already described for patients
suffering from myocardial infarction aggravated by
LBBB.14,15,25–27
In our study cohort, episodes of high-degree AVB were
observed in patients with preexisting BBB or BBB occurring
during TAVI. Two of the patients with preexisting BBB
developed high-degree AVB after permanent PM implanta-
tion but before TAVI. Because the range of symptoms of
high-degree AS and AVB overlap, it is a debatable point
whether transient episodes of high-degree AVB would have
been detected before hospital discharge without prophylactic
permanent PM implantation. These ﬁndings underline the
vulnerability of the cardiac conduction system and raise the
question whether an extension of postinterventional mon-
itoring might be reasonable in selected patients. Furthermore,
the periprocedural measurement of electrophysiologic
parameters might help to stratify patients according to their
risk for the development of AV conduction abnormalities.
In the absence of contraindications, temporary pacemaker
leads are commonly removed 48 to 72 hours after the
procedure, followed by a period of telemetric monitoring
for several days. With regard to episodes of new-onset high-
degree AVB detected after hospital discharge, the available
literature is inconsistent. The need for late permanent PM
implantation because of conduction abnormalities occurring
after hospital discharge has been reported repeatedly.18,28,29
In a survey of 65 patients conducted by Pereira et al,30
permanent PM implantation after hospital discharge was not
necessary. Moreover, a decline in pacemaker dependency
over time was recently demonstrated by Simms et al.31
Transient episodes of high-degree AVB may not be detected
safely by means of 12-lead ECG documentation at routine
follow-up visits.Study limitations
The use of certain PM devices allows continuous event
recording and enables post hoc assessment of documented
events. However, the memory storage volume of the respec-
tive PM is limited to the last 8 AVB episodes occurring before
pacemaker checkup. If patients die before a pacemaker
memory recall can be performed, data are irretrievably lost.
Accordingly, our results may even underestimate the actual
prevalence of high-degree AV conduction abnormalities in
such patients. The major limitation of the present data is the
small sample size. Our results are hypothesis-generating and
require conﬁrmation in larger patient cohorts. Furthermore, no
data are available about the frequency of conduction abnor-
malities in patients without BBB.
The clinical relevance of our ﬁndings can only be
hypothesized because the PM instantaneously switches to
DDD mode in case of high-degree AVB. Thus, we are notable to draw conclusions regarding the inﬂuence of these
episodes on clinical outcome and quality of life.
Another limitation is that the implantation depth of the
bioprosthesis was not measured in our study. However,
optimal positioning of the stent frame was aspired for every
single patient in order to avoid impairment of the cardiac
conduction system. Because all patients received the self-
expandable Medtronic CoreValve Revalving System, it is
not possible to extrapolate results to patients treated with
other devices.Conclusion
Patients with preexisting BBB or BBB occurring during
TAVI are at risk for the development of high-degree AVB.
Accordingly, intensiﬁed monitoring might be reasonable,
especially in patients treated with the self-expandable
Medtronic CoreValve Revalving System. Further prospec-
tive trials in greater numbers of patients are required to
conﬁrm our ﬁndings and determine the clinical need for
prophylactic permanent PM implantation.References
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Surg 2013;17:328–333.CLINICAL PERSPECTIVES
High-degree atrioventricular block ranks among the most common complications, especially in patients undergoing
transcatheter aortic valve implantation with the self-expandable Medtronic CoreValve Revalving System. According to
previous investigations, the majority of atrioventricular conduction abnormalities occurs during the intervention or shortly
thereafter. However, several authors have reported the need for delayed permanent pacemaker implantation because of the
late occurrence of high-degree atrioventricular block.
In the present study, we discovered a high incidence of high-degree atrioventricular bock episodes in patients with
preexisting or postprocedural new-onset intraventricular conduction abnormalities. Because of continuous monitoring by
means of intracardiac electrograms, we were able to detect episodes of high-degree atrioventricular block in patients who
would have been discharged without permanent pacemaker implantation according to currently available
recommendations.
Therefore, intensiﬁed monitoring might be reasonable at least for selected patients treated with the self-expandable
Medtronic CoreValve Revalving System. Furthermore, an electrophysiologic workup comparable to that recommended for
patients with bundle branch block and syncope might help to identify patients who presumably might beneﬁt from
permanent pacemaker implantation.
